Rani Therapeutics Holdings (RANI) Share-based Compensation (2021 - 2026)

Rani Therapeutics Holdings has reported Share-based Compensation for 6 years, with the latest figure at $21.0 billion in Q2 2026.

• On a quarterly basis, Share-based Compensation rose 155536.67% year-over-year to $21.0 billion in Q2 2026; TTM through Jun 2026 was $21.0 billion, a 155536.67% increase from a year earlier, with the FY2025 full-year figure at $12.9 million, down 30.07% from the prior year.
• Share-based Compensation was $21.0 billion for Q2 2026 at Rani Therapeutics Holdings, up from $12.7 million in the prior quarter.
• The five-year high for Share-based Compensation was $21.0 billion in Q2 2026, with the low at $2.2 million in Q4 2025.
• Average Share-based Compensation over 5 years is $1.2 billion, with a median of $4.6 million recorded in 2022.
• The sharpest annual moves came in 2022 and 2026: Share-based Compensation tumbled 76.45% in 2022, then jumped 155536.67% in 2026.
• Over 5 years, Share-based Compensation stood at $4.5 million in 2022, then dropped by 0.29% to $4.5 million in 2023, then dropped by 11.03% to $4.0 million in 2024, then slumped by 43.92% to $2.2 million in 2025, then soared by 937975.65% to $21.0 billion in 2026.
• The last three Share-based Compensation figures came in at $21.0 billion (Q2 2026), $12.7 million (Q1 2026), and $2.2 million (Q4 2025), per Business Quant data.